drugset / Trial / NCT01449279

Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy

NCT01449279 ↗

Phase 2 Completed 22 enrolled Stanford University
NaSingle-groupOpen-labelTreatment

Summary

To determine the safety of local palliative radiation therapy used in combination with anti-CTLA-4 immunotherapy.

Timeline

Start
2011-10
Primary completion
2015-12-31
Completion
2016-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 3 mg/kg Intravenous

Indications